Yahong Medicine Licenses APL-1702 to Theramex in Deal Worth Over $250M

The geography carve-out is the telling detail: Yahong keeps the rest of the world while handing Europe plus Australia, New Zealand and Turkey to a partner with local commercial reach, which suggests the economics of launching a women's health product in those markets favour licensing over going alone. The structure also front-loads relatively little cash relative to the headline total, so the real test is registration and uptake rather than the signing itself. Whether the near-term milestone is collected on schedule is the open question.